Cancer pain in advanced colorectal cancer
Conditions
Interventions
Experimental group:Xenopus capsule + Oxycontin
The control group:Placebo + OxyContin
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients with unresectable advanced metastatic colorectal cancer pain who received systemic chemotherapy, with or without targeted agents (cetuximab or bevacizumab or trastuzumab); (2) Patients with locally advanced colorectal cancer pain who received neoadjuvant chemotherapy with or without targeted agents (cetuximab or bevacizumab or trastuzumab) and the remaining neoadjuvant therapy course =30 days at the time of enrollment; (3) Moderate to severe cancer pain, NRS score > 3; (4) The syndrome differentiation of TCM belongs to the syndrome of qi stagnation and blood stasis; (5) KPS=60 points.
Exclusion criteria
Exclusion criteria: (1) Expected survival < 3 months; (2) non-cancerous pain, such as pain associated with tumor emergency and other neuropathic pain associated with tumor; (3) people who are allergic to the active ingredients in Xenopus capsule; (4) severe liver, heart and kidney dysfunction; (5) Patients with previous severe antitumor drug-related toxicity; (6) Patients with abnormal respiratory function, craniocerebral related history and hypotension; (7) Those who cannot cooperate with the treatment plan and have difficulty in making accurate judgments about their own pain and general conditions; (8) Patients who took proprietary Chinese medicine and Traditional Chinese medicine decoction related to tumor treatment within 30 days before enrollment; (9) patients who had received radiotherapy within 30 days before enrollment; (10) Patients who received radiotherapy plan within 14 days after enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome score; | — |
Countries
China
Contacts
Public ContactFengli
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed